Wells Fargo lowered the firm’s price target on GoodRx (GDRX) to $3.50 from $7 and keeps an Overweight rating on the shares. The firm acknowledges that unexpected take-rate reset reflects structural headwinds for Prescription Tx, but it also supports Pharma Direct’s growth formula. Near-term growth and margins are pressured, Wells argues.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: